Jan 21, 2020
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
Jan 14, 2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Jan 14, 2020
John Theurer Cancer Center Investigators Report Poor Colorectal Cancer Biomarker Testing Rates
Jan 13, 2020
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
Jan 13, 2020
Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference
Jan 09, 2020
Biotechnological Breakthroughs Help Revamp the Fight Against Cancer
Jan 09, 2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jan 08, 2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Jan 06, 2020
Mirati Therapeutics Announces Executive Management Changes
Dec 03, 2019
GO2 Foundation for Lung Cancer Announces Young Innovators Team Award Recipients
Nov 07, 2019
Trovagene Announces Third Quarter 2019 Results and Highlights
Nov 04, 2019
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
Oct 30, 2019
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Oct 24, 2019
Oblique Therapeutics Will be Presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020
Oct 17, 2019
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Oct 01, 2019
Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
Sep 28, 2019
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
Sep 17, 2019
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
Sep 08, 2019
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
Aug 27, 2019
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers